Phytoneering drugs for the treatment of cough: ways to provide the rational herbal medicine
DOI:
https://doi.org/10.24959/cphj.21.1545Keywords:
Bronchіpret, phytoneering, cough, treatment, rational therapyAbstract
Diseases of the respiratory system occupy an important place in the structure of morbidity in the population of Ukraine, being only second to diseases of the cardiovascular system in prevalence. Patients with a respiratory pathology make up a significant part of the pharmacy visitors. In most cases, at the first symptoms of such diseases, patients begin to be treated on their own with the help of non-prescription drugs, and quite often the first person they turn to is a pharmacist. A striking example of the effectiveness and safety of herbal medicine is the symptomatic treatment of cough as one of the most characteristic symptoms of the respiratory tract pathology. The use of herbal products with the antitussive, expectorant, mucolytic action has a long history, and currently it does not lose its significance. The clinical efficacy of herbal products is determined by the mechanism of their specific action, and the rational choice of the optimal drug taking into account the cause of the cough, its nature and the characteristics of the course of the inflammatory process in the respiratory organs, allows eliminating cough or effectively managing it. Bronchipret® is a herbal product of “Bionorica SE” company, which is one of the most studied and widely used in medical practice. The drug is indicated for the treatment of respiratory tract diseases accompanied by cough and sputum formation, including acute and chronic bronchitis. The main and well-studied pharmacological effects of Bronchipret® are secretolytic/mucolytic, anti-inflammatory, antiviral, antimicrobial and bronchospasmolytic ones. The pharmacological effects listed are due to a complex of biologically active substances (BAS) of such plants as the root of spring primrose, thyme herb, ivy leaf. All medicinal plants that make up the “active core” of the drug have a long history of their use in folk medicine. Moreover, their various beneficial effects on the human body in different diseases and conditions have been confirmed by empirical experience. The drug is produced in three dosage forms (drops, syrup, tablets), and it determines the targeting of its prescription to different categories of patients. The drug has a high evidence base and has been studied at the cellular and molecular levels.
Conclusions. In the case of choosing a herbal medicine for responsible self-medication, drug consumers can rely on their own experience, but most of them trust the knowledge of a pharmaceutical professional, and this fact increases the pharmacist’s responsibility for the treatment prescribed. Therefore, it should be the choice of a drug with an optimal efficacy/safety ratio, which is determined from the standpoint of evidence-based medicine. It is precisely these requirements that the phytoneering drug Bronchipret® meets.
References
Kardosh, P. (2019). Zdorovia Ukrainy, 18 (463), 43–44.
Kukes, V. G. (Ed.). (1999). Fitoterapiia s osnovami klinicheskiy farmakolohii. Moscow: Meditsina, 192.
Kardos, P. (2015). Phytotherapy in acute bronchitis: what is the evidence? Clinical Phytoscience, 1 (2). doi: 10.1186/s40816–015–0003–2.
Popp, M. (2019). Zdorov’ia Ukrainy: temat. nomer «Pediatriia», 4 (51), 23.
Zupanets, I. A., Popov, S. B., Rudyk, Yu. S. et al. (2018). Symptomy ta syndromy v praktychnii farmatsii. Pryntsypy terapii. Kharkiv: Zoloti storinky, 116.
Acute bronchitis. Phytotherapy instead of antibiotic: proactive communication! (2015). MMW Fortschr. Med., 157 (1), 66–67. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25767867.
Saust, L. T., Bjerrum, L., Siersma, V., Arpi, M., Hansen, M. P. (2018). Quality assessment in general practice: diagnosis and antibiotic treatment of acute respiratory tract infections. Scand. J. Prim. Health Care, 36 (4), 372–379. doi: 10.1080/02813432.2018.1523996.
Hubert, M. (2015). It need not always be an antibiotic. MMW Fortschr. Med., 157 (3), 67. doi: 10.1007/s15006–015–2707–0.
Hrodzinskyi, A. M. (Ed.). (1991). Likarski roslyny. Kyiv: Holov. red. URE, 544.
Popp, M. (2019). Zdorovia Ukrainy: temat. nomer «Pediatriia», 4 (51), 22.
Kovalenko, V. N. (Ed.). (2019). Kompendium 2019 – lekarstvennye preparaty. Kiev: Morion, 2560.
Begrow, F., Engelbertz, J., Feistel, B., Lehnfeld, R., Bauer, K., Verspohl, E. J. (2010). Impact of thymol in thyme extracts on their antispasmodic action and ciliary clearance. Planta Med., 76 (4), 311–318.
Seibel, J., Pergola, C., Werz, O., Kryshen, K., Wosikowski, K., Lehner, M. D., Haunschild, J. (2015). Bronchipret® syrup containing thyme and ivy extracts suppresses bronchoalveolarinfl ammation and goblet cell hyperplasia in experimental bronchoalveolitis. Phytomedicine, 1 (22 (13)), 1172–1177. doi: 10.1016/j.phymed.2015.09.001.
Wienkötter, N., Begrow, F., Kinzinger, U., Schierstedt, D., Verspohl, E. J. (2007). The effect of thyme extract on beta2-receptors and mucociliary clearance. Planta Med., 73 (7), 629–35. doi: 10.1055/s-2007-981535.
Seibel, J., Wonnemann, M., Werz, O., Lehne, M. D. (2018). A tiered approach to investigate the mechanism of anti-inflammatory activity of an herbal medicinal product containing a fixed combination of thyme herb and primula root extracts. Clinical Phytoscience, 4 (4). doi: 10.1186/s40816–018–0062–2.
Mastalerz-Migas, A., Doniec, Z., Płusa T. (2017). Bronchipret TE® in therapy of acute infections of the respiratory tract. Pol. Merkur. Lekarski, 22 (43 (258)), 255–257. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29298963.
Kemmerich, B. (2007). Evaluation of efficacy and tolerability of a fixed combination of dry extracts of thyme herb and primrose root in adults suffering from acute bronchitis with productive cough. A prospective, double-blind, placebo-controlled multicentre clinical trial. Arzneimittelforschung, 57 (9), 607–15. doi: https://doi.org/10.1055/s-0031-1296656.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
